ESC 2021 In the ENVISAGE-TAVI AF trial, the effect of edoxaban on net adverse clinical events (NACE) was compared to VKAs in elderly patients with AF who underwent TAVI.

ESC 2021 Which procedure is better when incidentally critical carotid artery stenosis is found; carotid surgery or stenting? Prof. Verheugt discusses findings of the ACST-2 trial.

ESC 2021 The QUARTET trial showed that starting with a quarter-dose quadruple combination pill led to greater BP lowering compared to starting with standard dose monotherapy in patients with hypertension.

ESC 2021 Two recent trials with fish oil, the REDUCE-IT trial and the STRENGTH trial, have shown conflicting results. How should we interpret these findings? Several lipid experts go through the evidence and provide their views.

ESC 2021 This pooled, post-hoc analysis of ORION-9, -10, and -11 showed that inclisiran significantly reduced LDL-c compared placebo in patients with and without polyvascular disease.

ESC 2021 The SANTORINI study aims to investigate whether the 2019 ESC/EAS guidelines for the management of dyslipidemia are being implemented across Europe.

ESC 2021 Prof. Pitt shares the results of the FIGARO-DKD trial. On top of optimized RAS blockade, the non-steroidal MRA finerenone significantly reduced the risk of the composite of time to CV death, non-fatal MI, non-fatal stroke or HF hospitalization.

ESC 2021 Prof. Bruce Neal discusses the results of the SSaSS study which showed that replacing dietary salt with a salt substitute reduced stroke, CV events and death, without increasing the risk of hyperkalemia.

ESC 2021 The Nature-PCSK9 trial, a naturally randomized target trial, showed a stepwise increase in the proportional reduction in lifetime risk of CV events with each earlier decade that LDL-c lowering was started by inhibiting PCSK9 with one-yearly dose of siRNA.

ESC 2021 After implantation of a stent in ACS patients, one-month DAPT followed by clopidogrel monotherapy did not demonstrate non-inferiority compared to 12-months DAPT for the net outcome of CV events and bleedings.

ESC 2021 The 2021 guidelines on CVD prevention in clinical practice contain recommendations at the individual and the population level. New at the individual level is a stepwise approach to intensify preventive treatments.

ESC 2021 The STEP study showed that intensive BP lowering (SBP target 110 to <130 mmHg) reduced the risk of CV events in older patients with hypertension, compared to standard treatment (SBP target 130 to <150 mmHg).